<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN" "JATS-archive-oasis-article1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" id="tra12820" dtd-version="1.1" xml:lang="en" article-type="research-article" specific-use="VoR">
<front>
<journal-meta>
<journal-id journal-id-type="doi">10.1111/(ISSN)1600-0854</journal-id>
<journal-id journal-id-type="publisher-id">TRA</journal-id>
<journal-title-group>
<journal-title xml:lang="en">Traffic</journal-title>
<abbrev-journal-title abbrev-type="publisher" xml:lang="en">Traffic</abbrev-journal-title>
</journal-title-group>
<issn publication-format="ppub">1398-9219</issn>
<issn publication-format="epub">1600-0854</issn>
<publisher>
<publisher-name>John Wiley &amp; Sons A/S</publisher-name>
<publisher-loc>Former Munksgaard</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1111/tra.12820</article-id>
<article-id pub-id-type="publisher-id">TRA12820</article-id>
<article-categories>
<subj-group subj-group-type="overline" xml:lang="en">
<subject>ORIGINAL ARTICLE</subject>
</subj-group>
<subj-group subj-group-type="heading" xml:lang="en">
<subject>ORIGINAL ARTICLES</subject>
</subj-group>
</article-categories>
<title-group>
<article-title xml:lang="en"><styled-content style="fixed-case" toggle="no">EAP45</styled-content> association with budding <styled-content style="fixed-case" toggle="no">HIV</styled-content>‐1: Kinetics and domain requirements</article-title>
<alt-title alt-title-type="left-running-head">Meng et al.</alt-title>
</title-group>
<contrib-group>
<contrib id="tra12820-cr-0001" contrib-type="author">
<name>
<surname>Meng</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="aff" rid="tra12820-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="tra12820-cr-0002" contrib-type="author">
<name>
<surname>Vallejo Ramirez</surname>
<given-names>Pedro P.</given-names>
</name>
<xref ref-type="aff" rid="tra12820-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib id="tra12820-cr-0003" contrib-type="author">
<name>
<surname>Scherer</surname>
<given-names>Katharina M.</given-names>
</name>
<xref ref-type="aff" rid="tra12820-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib id="tra12820-cr-0004" contrib-type="author">
<name>
<surname>Bruggeman</surname>
<given-names>Ezra</given-names>
</name>
<xref ref-type="aff" rid="tra12820-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib id="tra12820-cr-0005" contrib-type="author">
<name>
<surname>Kenyon</surname>
<given-names>Julia C.</given-names>
</name>
<xref ref-type="aff" rid="tra12820-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="tra12820-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="tra12820-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib id="tra12820-cr-0006" contrib-type="author" corresp="yes">
<name>
<surname>Kaminski</surname>
<given-names>Clemens F.</given-names>
</name>
<email>cfk23@cam.ac.uk</email>
<xref ref-type="corresp" rid="correspondenceTo">*</xref>
<xref ref-type="aff" rid="tra12820-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib id="tra12820-cr-0007" contrib-type="author" corresp="yes">
<name>
<surname>Lever</surname>
<given-names>Andrew M.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9819-4453</contrib-id>
<email>amll1@medschl.cam.ac.uk</email>
<xref ref-type="corresp" rid="correspondenceTo">*</xref>
<xref ref-type="aff" rid="tra12820-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="tra12820-aff-0005">
<sup>5</sup>
</xref>
</contrib>
</contrib-group>
<aff id="tra12820-aff-0001">
<label>
<sup>1</sup>
</label>

<named-content content-type="organisation-division">Department of Medicine</named-content>

<institution>University of Cambridge, Addenbrooke's Hospital</institution>

<city>Cambridge</city>
 <country country="GB">UK</country>

</aff>
<aff id="tra12820-aff-0002">
<label>
<sup>2</sup>
</label>

<named-content content-type="organisation-division">Laser Analytics Group, Department of Chemical Engineering and Biotechnology</named-content>

<institution>University of Cambridge</institution>

<city>Cambridge</city>
 <country country="GB">UK</country>

</aff>
<aff id="tra12820-aff-0003">
<label>
<sup>3</sup>
</label>

<named-content content-type="organisation-division">Department of Microbiology and Immunology</named-content>

<institution>National University of Singapore</institution>

<city>Singapore</city>
 <country country="SG">Singapore</country>

</aff>
<aff id="tra12820-aff-0004">
<label>
<sup>4</sup>
</label>

<institution>Homerton College, University of Cambridge</institution>

<city>Cambridge</city>
 <country country="GB">UK</country>

</aff>
<aff id="tra12820-aff-0005">
<label>
<sup>5</sup>
</label>

<named-content content-type="organisation-division">Department of Medicine</named-content>

<institution>National University of Singapore</institution>

<city>Singapore</city>
 <country country="SG">Singapore</country>

</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>

<bold>Correspondence</bold><break/>
Clemens F. Kaminski, Laser Analytics Group, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.<break/>
Email: <email>cfk23@cam.ac.uk</email>
<break/>


Andrew M. Lever, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.<break/>
Email: <email>amll1@medschl.cam.ac.uk</email>
<break/>

</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><day>03</day>
<month>10</month>
<year>2021</year>
</pub-date><fpage/><lpage/><history>

<date date-type="rev-recd">
<day>25</day>
<month>08</month>
<year>2021</year>
</date>

<date date-type="received">
<day>28</day>
<month>01</month>
<year>2021</year>
</date>

<date date-type="accepted">
<day>23</day>
<month>09</month>
<year>2021</year>
</date>

</history>
<permissions>
<copyright-statement content-type="issue-copyright">© 2021 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</copyright-statement>
<copyright-statement content-type="article-copyright">© 2021 The Authors. <italic>Traffic</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>© 2021 The Authors. Traffic published by John Wiley &amp; Sons Ltd.</copyright-holder>
<license>
<ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract xml:lang="en" abstract-type="main">
<title>Abstract</title>
<p xml:lang="en">A number of viruses including HIV use the ESCRT system to bud from the infected cell. We have previously confirmed biochemically that ESCRT‐II is involved in this process in HIV‐1 and have defined the molecular domains that are important for this. Here, using SNAP‐tag fluorescent labelling and both fixed and live cell imaging we show that the ESCRT‐II component EAP45 colocalises with the HIV protein Gag at the plasma membrane in a temporal and quantitative manner, similar to that previously shown for ALIX and Gag. We show evidence that a proportion of EAP45 may be packaged within virions, and we confirm the importance of the N terminus of EAP45 and specifically the H0 domain in this process. By contrast, the Glue domain of EAP45 is more critical for recruitment during cytokinesis, emphasising that viruses have ways of recruiting cellular components that may be distinct from those used by some cellular processes. This raises the prospect of selective interference with the pathway to inhibit viral function while leaving cellular functions relatively unperturbed.</p>
</abstract>
<kwd-group kwd-group-type="author-generated" xml:lang="en">
<kwd id="tra12820-kwd-0001">budding</kwd>
<kwd id="tra12820-kwd-0002">colocalisation</kwd>
<kwd id="tra12820-kwd-0003">ESCRT</kwd>
<kwd id="tra12820-kwd-0004">gag</kwd>
<kwd id="tra12820-kwd-0005">HIV</kwd>
<kwd id="tra12820-kwd-0006">TIRF</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-0001">
<funding-source>

<institution-wrap>
<institution>Engineering and Physical Sciences Research Council</institution>
<institution-id>http://dx.doi.org/10.13039/501100000266</institution-id>
</institution-wrap>

</funding-source>
<award-id>EP/H018301/1</award-id>
<award-id>EP/L015889/1</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0002">
<funding-source>

<institution-wrap>
<institution>Gates Cambridge Scholarship</institution>
</institution-wrap>

</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0003">
<funding-source>

<institution-wrap>
<institution>Infinitus China Ltd</institution>
</institution-wrap>

</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0004">
<funding-source>

<institution-wrap>
<institution>Medical Research Council</institution>
<institution-id>http://dx.doi.org/10.13039/501100007155</institution-id>
</institution-wrap>

</funding-source>
<award-id>MR/K015850/1</award-id>
<award-id>MR/K02292X/1</award-id>
<award-id>MR/N0229939/1</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0005">
<funding-source>

<institution-wrap>
<institution>MedImmune</institution>
<institution-id>http://dx.doi.org/10.13039/501100004628</institution-id>
</institution-wrap>

</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0006">
<funding-source>

<institution-wrap>
<institution>Microbiology Society</institution>
<institution-id>http://dx.doi.org/10.13039/501100007901</institution-id>
</institution-wrap>

</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0007">
<funding-source>

<institution-wrap>
<institution>RCUK Technology Touching Life Initiative</institution>
</institution-wrap>

</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group id="funding-0008">
<funding-source>

<institution-wrap>
<institution>Wellcome Trust</institution>
<institution-id>http://dx.doi.org/10.13039/100010269</institution-id>
</institution-wrap>

</funding-source>
<award-id>089703/Z/09/Z</award-id>
<award-id>203249/Z/16/Z</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="0"/>
<page-count count="15"/>
<word-count count="11048"/>
</counts>
</article-meta>
</front>
</article>